-
Abanico Coffee Roasters Opens Second San Francisco Location in Inner Sunset
-
San Ġiljan Defeat Paredes 20-12 in Challenger Cup Opener
-
Trump Threatens Heavy Taxes on US Firms Building Data Centers Abroad
-
Kuwait DGCA Delegation Attends ICAO Assembly in Montreal
-
Gozo Minister Clint Camilleri Appointed CPMR Vice-President for Maritime Affairs
-
Charlie Puth and Ellie Goulding to Headline First Johnnie & Co. Festival in Mumbai
-
ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances
-
Maryland Woman Arrested in Decade-Long Cancer Scam Involving Fake Medical Team
-
Panthers Seek NFC South Lead Against Ravens as Baltimore Ends Skid
-
AsiaFIN Holdings Corp. Appoints Fortune Angel INC as U.S. Reseller Partner to Expand Its Agentic and Robotic Process Automation SaaS Business Across New York and the East Coast
-
5 Fun Date Night Ideas That Don't Cost a Fortune
-
Closing a Business with Payroll Taxes Owed - Clear Start Tax Explains the Trust Fund Recovery Penalty
-
Dateline appoints Tony Ferguson as Acting Chairman
-
American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities
-
AI Search Engineers Says Longer AI Mode Questions Mean Professional Service Firms Should Answer Full Client Questions Directly on Their Pages
-
Arrive AI's Pro Forma Stockholders' Equity Now Above Nasdaq Minimum Requirement Following Recent Transactions
-
Who Does the Best Rhinoplasty in Sarasota?
-
PodcastOne (NASDAQ:PODC) Launches People Pleasers Podcast hosted by Comedians Leah Rudick and Jessica Michelle Singleton
-
Alset AI Closes Non-Brokered Private Placement Offering
-
Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
-
barq Signs MoU with TenPay Global to Enhance Remittances and Digital Payments in China
-
American Resources Corporation and ReElement Technologies Selected as Part of Winning U.S.-Led Consortium for Kenya's Strategic Mrima Hill Critical Minerals Project
-
Ryde Group Ltd Announces Non-Binding Term Sheet for Proposed Minority Investment in Multi Genius Limited and MOU on Technology Collaboration
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 20
-
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure
-
The DEA Laid The Trap - And State Marijuana Operators Took The Bait
-
Karviva Introduces Unwined Alcohol-Free Malbec and Rose Varieties
-
IDLife Earns Elite 9.04 Brand TrustScore(R) From SuppCo
-
Fortitude Gold Closes $10 Million Private Placement
-
APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence
-
APEX Honors Aeroméxico CEO Dr. Andrés Conesa with Historic APEX CEO Lifetime Achievement Award
-
Enmarket to Open Newest Eatery Location in Rincon, GA
-
Eylsia Nicolas Hits No. 1 on Groover's Global and US Singer-Songwriter Charts with "One More Moment," as Taglish Preview of "Wake Me Up for Christmas" Passes One Million Views in Under 24 Hours
-
What Is the Best Social Media Platform for Peptides?
-
WhalesBot Advances Creativity-Driven AI and Coding Education Through Pubbo AI
-
Cytta Air Expands Military Contracting Expertise - Appoints Rear Admiral James "Gib" Godwin III to Advisory Board
-
Tidal Wave Auto Spa Opens New Locations in Murfreesboro, Tennessee and Asheville, North Carolina This Week
-
Peoples Bancorp Announces Cash Dividend
-
Jaguar Health, Inc. Announces Reverse Stock Split
-
Kartoon Studios' Beacon Media Partners With Bandai on Tamagotchi's Landmark 30th Anniversary Times Square Celebration
-
First Phosphate and Zeo Energy Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
-
Taylor Bank Announces $125,000 Commitment to Diakonia's Supportive Living Campus Capital Campaign
-
Ondas, Palantir and Regna AI Host Key Defense Technology Leaders to Accelerate the Path from AI Innovation to Fielded Capability
CS Interpharm and CS Diagnostics Pharma Complete Conversion of Preferred Shares to Common Stock, Strengthening CSDX's Path to Consolidated Financial Reporting
CHEYENNE, WYOMING / ACCESS Newswire / October 31, 2025 / CS Diagnostics Corp. (OTCQB:CSDX), is a Wyoming-incorporated company with principal operations in Cheyenne, Wyoming. The Company designs, manufactures, and distributes advanced medical and wellness products while driving innovation in diagnostics and pharmaceuticals. As part of the CS Group, CSDX and its affiliates serve national and international markets, dedicated to improving patient care and advancing global health, today announced that its key affiliate companies, CS Interpharm and CS Diagnostics Pharma, have successfully completed the conversion of their holdings in the Company's Series B Preferred Stock into unrestricted common stock.
This milestone marks a pivotal advancement in CSDX's strategic roadmap to consolidate financial statements across all affiliated entities by fiscal year-end, December 31, 2025, enabling a more integrated, transparent, and streamlined reporting framework.
Strategic Alignment for Growth and Transparency
Together, CSDX, CS Interpharm, and CS Diagnostics Pharma form a unified group driving innovation in advanced medical, wellness products and life sciences. The Series B Preferred Shares-originally issued to support strategic investments and align affiliate operations-carried dividend preferences and conversion rights.
Following a comprehensive capital structure review, the decision to convert these shares reflects CSDX's commitment to simplification, governance, and long-term value creation. This conversion reduces complexities in financial reporting, eliminates preferred dividend tracking, and establishes a single equity class that better represents the unified organization.
"This share conversion is not merely a technical adjustment but a forward-thinking strategic initiative that underscores our commitment to unity, innovation, and sustainable growth," said Mohammad EsSayed, Principal Financial Officer of CS Diagnostics Corp. "By integrating our affiliates' interests through common shares, we are better equipped to leverage collective expertise in advanced medical, wellness products and life sciences, driving enhanced value for our shareholders as we prepare for fully consolidated financial presentations."
Key Benefits of the Conversion
Enhanced Transparency:
The consolidation will offer investors a complete view of the group's performance, integrating revenue, assets, and operations. Combined financials will reflect product sales, service contracts, and research developments across all entities-providing a holistic picture of CSDX's business strength.
Improved Efficiency:
Aligning share classes streamlines corporate administration, reducing overhead from managing preferred instruments and allowing management to focus on innovation, operational execution, and growth initiatives.
Value Creation for Shareholders:
Affiliates now participate directly in CSDX's growth trajectory as common shareholders, increasing alignment and liquidity while mitigating dilution risks from unconverted preferred shares.
Stronger Capital Market Position:
A unified equity structure enhances CSDX's attractiveness to investors and partners by presenting a cleaner balance sheet, improving access to capital markets, and supporting potential future uplisting or strategic collaborations.
Maintaining Market Integrity and Compliance
To ensure orderly trading conditions, resales of converted shares by affiliates remain subject to Rule 144 of the Securities Act of 1933, including:
Form 144 Filings: Required for resales exceeding 5,000 shares or $50,000 in aggregate market value within any three-month period.
Volume Restrictions: Limited to the greater of 1% of the outstanding shares of the same class or the average weekly trading volume over the prior four calendar weeks preceding the filing of the Form 144.
Public Information: The Company will maintain current public filings to meet disclosure standards.
Manner of Sale: Resales must be conducted through ordinary brokerage transactions or directly with a market maker, without solicitation of buyers or payment of extraordinary commissions.
These measures underscore CSDX's commitment to ethical practices, investor protection, and long-term shareholder confidence.
Looking Ahead
With consolidated financial reporting on the horizon, CSDX anticipates significant operational synergies across its group-ranging from shared R&D pipelines and supply chain optimization to enhanced product development collaboration. The integration of affiliate revenues and profits will reinforce CSDX's growth, profitability, and competitive position in global medical and life sciences markets.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits of share conversion, financial consolidation, operational synergies, and future growth. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including changes in market conditions, regulations, and economic factors. The Company undertakes no obligation to update these statements except as required by law. This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events. Actual results achieved may vary from the information provided herein because of numerous known and unknown risks, uncertainties, and other factors.
For further information please visit https://csdcorp.us
or contact
Mohammad Essayed
Email: [email protected]
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
R.Chavez--AT